Key points
- Board reassessment identifies potentially faster pathway into US$5.9 billion USA IVF market
- Identified a medical device as a predicate for FDA's 510(k) clearance pathway
- Pre-Submission engagement with FDA planned to seek feedback before formal submission
Full summary
Memphasys Limited has identified a potentially faster pathway to enter the US IVF market, valued at approximately $5.9 billion. The company's board reassessed its US regulatory strategy and identified a medical device that could serve as a predicate for the FDA's 510(k) clearance pathway, which is more established than the previously contemplated De Novo pathway. Memphasys plans to engage with the FDA in a Pre-Submission process to seek feedback before proceeding with a formal submission. The US market represents a significant long-term opportunity with over 500 clinics providing assisted reproductive technology services annually.
Outlook
Memphasys plans to pursue the FDA's 510(k) clearance pathway for its Felix device, which could expedite entry into the US IVF market. The company will engage with the FDA to seek feedback before making a formal submission.